CBIO Q1 2022 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$345M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$258,122

Operating Income

-$15M

Net Income

-$15M

EPS (Diluted)

$-0.28

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$81M

Total Liabilities

$13M

Stockholders' Equity

$68M

Cash & Equivalents

$77M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$1M	-100.0%
Gross Profit	-$258,122	$1M	-124.5%
Operating Income	-$15M	-$14M	-2.7%
Net Income	-$15M	-$14M	-2.7%